TMED3

TMED3 is a p24-family endoplasmic reticulum-to-Golgi cargo protein that recognizes ER core-glycosylated transmembrane cargos and, as a subunit of a heteromeric TMED2/3/9/10 complex, mediates ER stress-associated unconventional (Golgi-independent) secretion of transmembrane proteins including CFTR, pendrin, and SARS-CoV-2 Spike; co-expression of all four TMEDs improves this secretion while individual silencing reduces it (PMID:35748162). Beyond this trafficking role, TMED3 acts as a context-dependent modulator of oncogenic signaling. In colon cancer it positively modulates WNT-TCF signaling and behaves as a metastatic suppressor, with its knockdown increasing metastatic growth (PMID:24920608); this WNT-TCF–promoting activity is opposed by TMED9, which is upregulated upon TMED3 loss and drives a pro-metastatic CNIH4/TGFα/GLI axis, defining a TMED3→TMED9 antagonism that balances WNT-TCF and GLI signaling (PMID:31253868). In ovarian cancer, TMED3 stabilizes SMAD2 by counteracting NEDD4 E3 ligase-mediated ubiquitination (PMID:38411267). The literature places TMED3 upstream of multiple downstream effectors, but most of these connections rest on lower-confidence transcriptomic and epistatic studies in individual tumor types; the precise biochemical mechanism by which TMED3 engages these signaling pathways has not been resolved in the available corpus.

1. 2014 Medium

   Established that TMED3 is a functional modulator of WNT-TCF signaling and, unexpectedly, a suppressor of metastasis rather than a generic oncogene.

   Evidence Genome-wide in vivo RNAi screen in primary human colon tumor cells with WNT-TCF reporter assays and xenografts

   PMID:24920608

   Open questions at the time

   • No direct biochemical mechanism linking TMED3 to WNT-TCF components
   • Metastatic suppression shown in xenografts but not in autochthonous models
2. 2016 Low

   Extended TMED3 function to hepatocellular carcinoma, where it appeared to act as a pro-metastatic factor via IL-11/STAT3 signaling, hinting at tissue-context-dependent roles.

   Evidence Gene microarray of TMED3-knockdown HCC cells with overexpression/knockdown functional assays and in vivo metastasis models

   PMID:27901021

   Open questions at the time

   • IL-11/STAT3 link inferred from microarray without direct mechanistic confirmation
   • Opposite directionality from colon cancer not reconciled mechanistically
3. 2019 Medium

   Resolved the epistatic relationship between TMED3 and its paralog TMED9, showing antagonistic control of WNT-TCF versus a CNIH4/TGFα/GLI pro-metastatic axis.

   Evidence RNAi knockdown with transcriptional rescue and migration assays in three colon cancer lines plus xenografts

   PMID:31253868

   Open questions at the time

   • Molecular basis of TMED3-TMED9 antagonism not defined
   • How TMED3 loss upregulates TMED9 is unknown
4. 2019 Medium

   Placed TMED3 downstream of miR-876-3p in controlling chemoresistance and stem-like properties, establishing a regulatory input on TMED3 expression.

   Evidence Luciferase reporter and biotin-miRNA pulldown confirming direct targeting, with siRNA functional rescue in gastric cancer cells

   PMID:30843262

   Open questions at the time

   • Effector mechanism downstream of TMED3 in this axis not defined
   • Single cancer-type context
5. 2020 Low

   Associated TMED3 with Wnt/β-catenin pathway activation in breast cancer, broadening its signaling connections beyond colon WNT-TCF.

   Evidence Overexpression/knockdown assays with Western blot and immunofluorescence of Wnt/β-catenin components

   PMID:32606792

   Open questions at the time

   • Pathway association by protein expression without direct mechanistic dissection
   • No demonstrated physical interaction
6. 2021 Low

   A series of tumor-specific studies positioned TMED3 upstream of diverse downstream effectors (EZR, RPS15A, AKT, pro-survival nodes, lncRNA/miR axes) across multiple cancers.

   Evidence Transcriptomic profiling, apoptosis/protein arrays, and epistatic rescue across LUSC, osteosarcoma, NSCLC, chordoma, and breast cancer with xenografts

   PMID:33760171 PMID:34130584 PMID:34429402 PMID:34758370 PMID:34838013

   Open questions at the time

   • Downstream targets identified largely by transcriptomic screens with partial rescue
   • No direct biochemical interactions established for most effectors
   • Pathway mechanisms inferred via inhibitors rather than reconstitution
7. 2022 High

   Defined the core molecular function of TMED3: recognition of ER core-glycosylated transmembrane cargos and assembly into a TMED2/3/9/10 complex driving Golgi-independent unconventional secretion.

   Evidence Combinatorial siRNA silencing, ΔF508-CFTR and pendrin ion-transport assays, SARS-CoV-2 release assay, and co-expression studies

   PMID:35748162

   Open questions at the time

   • Structural basis of cargo recognition not resolved
   • Stoichiometry and assembly order of the TMED2/3/9/10 complex unknown
   • Link between this trafficking function and cancer signaling roles not established
8. 2022 Low

   Identified FAM60A as a downstream gene mediating TMED3 pro-tumorigenic effects in esophageal squamous cell carcinoma.

   Evidence Affymetrix microarray and IPA with FAM60A knockdown rescue in vitro and in vivo

   PMID:35358714

   Open questions at the time

   • Downstream target identified by transcriptomics with partial rescue
   • No direct mechanistic link from TMED3 to FAM60A
9. 2023 Low

   Reported a physical interaction between TMED3 and CDCA8 placing TMED3 upstream of PI3K/AKT signaling in melanoma.

   Evidence Interaction assay with CDCA8 and AKT-activator (SC79) rescue plus Western blot for PI3K/AKT phosphorylation

   PMID:36991473

   Open questions at the time

   • Single Co-IP/pulldown without reciprocal validation
   • Mechanism by which the interaction modulates PI3K/AKT not defined
10. 2024 Medium

    Provided a more concrete biochemical mechanism: TMED3 stabilizes SMAD2 by antagonizing NEDD4-mediated ubiquitination in ovarian cancer.

    Evidence shRNA knockdown, SMAD2 functional rescue, and ubiquitination assays with xenografts

    PMID:38411267

    Open questions at the time

    • Ubiquitination assay methodology not detailed
    • Whether TMED3 directly binds SMAD2 or NEDD4 not shown
11. 2024 Low

    Linked TMED3 activity to FOXO1a/FOXO3a phosphorylation in prostate cancer, extending its signaling footprint.

    Evidence shRNA knockdown with KEGG enrichment and Western blot for FOXO phosphorylation in vitro and in vivo

    PMID:39735675

    Open questions at the time

    • Direct biochemical mechanism linking TMED3 to FOXO phosphorylation not established
    • No identified kinase intermediary

• How TMED3's core ER-to-Golgi cargo-trafficking and unconventional-secretion function mechanistically connects to its diverse, often opposing, roles in cancer signaling remains unresolved.
• No unifying model reconciling metastatic-suppressor versus pro-tumorigenic phenotypes across tissues
• Whether cancer signaling effects derive from cargo trafficking is untested
• Structural and stoichiometric details of the TMED2/3/9/10 complex unknown